Pearson J G
Am J Med. 1985 Sep 20;79(3B):67-71. doi: 10.1016/s0002-9343(85)80010-3.
The pharmacokinetics of glyburide can be described by a two-compartment open model. Terminal-phase descriptions are formulation-dependent and are complicated by apparent food-associated mobilization of drug from the stomach. Some researchers indicate a possible third (or deep) compartment, but this appears to be an artifact of a nonspecific drug assay. Although no accumulation has been observed in short-term studies, further investigation of the possibility of drug accumulation with long-term therapy is needed. Distribution of glyburide is affected by high affinity for serum albumin (99 percent bound), and elimination of the drug appears to be evenly divided between biliary and renal routes. The biologic half-life of glyburide is not significantly correlated with renal function in subjects with creatinine clearances of 30 ml/minute/1.7 m2 or more. Gradations in disease state, multiple sites of sulfonylurea action, and inter-patient variability have made it difficult to relate biologic response to glyburide serum levels.
格列本脲的药代动力学可用二室开放模型来描述。终末相的描述取决于制剂,且因药物从胃中与食物相关的明显动员而变得复杂。一些研究人员指出可能存在第三个(或深部)房室,但这似乎是一种非特异性药物测定的假象。虽然在短期研究中未观察到药物蓄积,但仍需要进一步研究长期治疗时药物蓄积的可能性。格列本脲的分布受其对血清白蛋白的高亲和力(99%结合)影响,药物的消除似乎在胆汁和肾脏途径之间平均分配。在肌酐清除率为30 ml/分钟/1.7 m²或更高的受试者中,格列本脲的生物半衰期与肾功能无显著相关性。疾病状态的分级、磺酰脲类药物作用的多个部位以及患者间的变异性使得难以将生物反应与格列本脲血清水平联系起来。